These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9613688)

  • 1. Vancomycin use and monitoring in pediatric patients in a community hospital.
    Kahyaoglu O; Akpinar M; Nolan B; Inoue S; Zureikat G; Kumar A
    Infect Control Hosp Epidemiol; 1998 May; 19(5):299, 301. PubMed ID: 9613688
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of antimicrobial stewardship program on vancomycin use in a pediatric teaching hospital.
    Di Pentima MC; Chan S
    Pediatr Infect Dis J; 2010 Aug; 29(8):707-11. PubMed ID: 20182398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of vancomycin therapeutic drug monitoring trends at pediatric hospitals.
    Moffett BS; Edwards MS
    Pediatr Infect Dis J; 2013 Jan; 32(1):32-5. PubMed ID: 22926218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of guidelines on vancomycin use at a Hong Kong teaching hospital.
    Lee VW; Lyon DJ; Fung KS; Leung TP; Ng JK; You JH
    Am J Health Syst Pharm; 2003 May; 60(9):949-50. PubMed ID: 12756948
    [No Abstract]   [Full Text] [Related]  

  • 5. Knowledge of Centers for Disease Control and Prevention guidelines for the use of vancomycin at a large tertiary care children's hospital.
    Lin PL; Oram RJ; Lauderdale DS; Dean R; Daum RS
    J Pediatr; 2000 Nov; 137(5):694-700. PubMed ID: 11060537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vancomycin utilization at a teaching hospital in Hong Kong.
    You JH; Lyon DJ; Lee BS; Kwan SM; Tang HY
    Am J Health Syst Pharm; 2001 Nov; 58(22):2167-9. PubMed ID: 11760919
    [No Abstract]   [Full Text] [Related]  

  • 7. A retrospective drug utilization evaluation of vancomycin usage in paediatric patients.
    Hing WC; Bek SJ; Lin RT; Li SC
    J Clin Pharm Ther; 2004 Aug; 29(4):359-65. PubMed ID: 15271103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Monitoring of vancomycin in pediatrics].
    Delicourt A; Touzin K; Lavoie A; Therrien R; Lebel D
    Med Mal Infect; 2012 Apr; 42(4):167-70. PubMed ID: 22424794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vancomycin use in a hospital with vancomycin restriction.
    Roghmann MC; Perdue BE; Polish L
    Infect Control Hosp Epidemiol; 1999 Jan; 20(1):60-3. PubMed ID: 9927270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin: over 50 years later and still a work in progress.
    Rybak MJ; Rotschafer JC; Rodvold KA
    Pharmacotherapy; 2013 Dec; 33(12):1253-5. PubMed ID: 24302197
    [No Abstract]   [Full Text] [Related]  

  • 11. Effectiveness of a guideline to reduce vancomycin use in the neonatal intensive care unit.
    Chiu CH; Michelow IC; Cronin J; Ringer SA; Ferris TG; Puopolo KM
    Pediatr Infect Dis J; 2011 Apr; 30(4):273-8. PubMed ID: 21085051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of vancomycin therapeutic drug monitoring recommendations in Scotland.
    Helgason KO; Thomson AH; Ferguson C
    J Antimicrob Chemother; 2008 Jun; 61(6):1398-9. PubMed ID: 18349039
    [No Abstract]   [Full Text] [Related]  

  • 13. Vancomycin use in pediatric hematology-oncology patients.
    Hopkins HA; Sinkowitz-Cochran RL; Rudin BA; Keyserling HL; Jarvis WR
    Infect Control Hosp Epidemiol; 2000 Jan; 21(1):48-50. PubMed ID: 10656357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug use density in critically ill children and newborns: analysis of various methodologies.
    Valcourt K; Norozian F; Lee H; Raszynski A; Torbati D; Totapally BR
    Pediatr Crit Care Med; 2009 Jul; 10(4):495-9. PubMed ID: 19451853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vancomycin use in pediatric cardiothoracic surgery patients.
    Shah SS; Sinkowitz-Cochran RL; Keyserling HL; Jarvis WR
    Pediatr Infect Dis J; 1999 Jun; 18(6):558-60. PubMed ID: 10391192
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of antimicrobial guidelines for community-acquired pneumonia in children.
    Smith MJ; Kong M; Cambon A; Woods CR
    Pediatrics; 2012 May; 129(5):e1326-33. PubMed ID: 22492769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vancomycin and ceftazidime bioactivities persist for at least 2 weeks in the lumen in ports: simplifying treatment of port-associated bloodstream infections by using the antibiotic lock technique.
    Haimi-Cohen Y; Husain N; Meenan J; Karayalcin G; Lehrer M; Rubin LG
    Antimicrob Agents Chemother; 2001 May; 45(5):1565-7. PubMed ID: 11302830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of linezolid and vancomycin treatment on local signs and symptoms of inflammation among pediatric patients with complicated skin and skin structure infections.
    Deville JG; Equils O; Huang DB; Ang JY
    Clin Pediatr (Phila); 2011 Nov; 50(11):1064-7. PubMed ID: 21098522
    [No Abstract]   [Full Text] [Related]  

  • 19. Vancomycin-resistant-enterococci--colonization of 24 patients on a pediatric oncology unit.
    Schuster F; Graubner UB; Schmid I; Weiss M; Belohradsky BH
    Klin Padiatr; 1998; 210(4):261-3. PubMed ID: 9743963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Point prevalence survey of antimicrobial utilization in the cardiac and pediatric critical care unit.
    Blinova E; Lau E; Bitnun A; Cox P; Schwartz S; Atenafu E; Yau Y; Streitenberger L; Parshuram CS; Marshall J; Seto W
    Pediatr Crit Care Med; 2013 Jul; 14(6):e280-8. PubMed ID: 23823209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.